



# Effects of *Scilla autumnalis* Extracts on U87-MG Human Glioblastoma Cells

*Scilla autumnalis* Ekstrelerinin U-87 MG İnsan Glioblastoma Hücreleri Üzerinde Etkileri

Murat Pekmez<sup>1</sup>, Gagatay Tarhan<sup>1</sup>, Ali Zeytinluoğlu<sup>2</sup>, Murat Turan<sup>3</sup>, Sefika Beyza Mete<sup>1</sup>, Aylin Koseler<sup>4</sup>

<sup>1</sup>Department of Molecular Biology and Genetics, Istanbul University Faculty of Science, Istanbul; <sup>2</sup>Department of Electronics and Automation, Pamukkale University Vocational School of Technical Sciences, Denizli; <sup>3</sup>Department of Molecular Biology and Genetics, Faculty of Science, Erzurum Technical University, Erzurum; <sup>4</sup>Department of Biophysics, Pamukkale University Faculty of Medicine, Denizli, Turkey

## ABSTRACT

**Aim:** This study aimed to measure the effects of *Scilla autumnalis* extracts which might act as potential plant based chemotherapeutic, on U87 glioblastoma cell line.

**Material and Method:** Cytotoxicity assays were performed by determining the cell viability of the samples with MTT (3 – (4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide). Gene expression levels of glucose transporter 1 (GLUT1), Glucose transporter 3 (GLUT3), Glucose transporter 4 (GLUT4), Hexokinase 1 (HK1) and Hexokinase 2 (HK2), multidrug resistance1 (MDR1), Cytochrome P450 Family 2 Subfamily E Member 1 (CYP2E1) and Pregnane X receptor (PXR) was analyzed in glioblastoma cells using quantitative real-time RT-PCR.

**Results:** According to the analysis, we observed a 10% increase in the expression of Glut1, however, we did not observe a difference in Glut3 expression. For Glut4, root ethanol extract decreased its expression by 13% but shoot extracts elevated the expression levels by only 5–6%. We determined the low expression levels of HK1 and HK2 in glioblastoma compared to the control group. *S.autumnalis* root extract led to a slight increase in MDR1 expression. We found that the expression level of CYP2E1 was 20% lower in glioblastoma cells treated with *Scilla autumnalis* root and shoots extracts compared to the control group. We determined downregulation in PXR expression.

**Conclusion:** This study may contribute significantly to the understanding of the cytotoxic effect of *Scilla autumnalis*. This approach may allow the possibility of *Scilla autumnalis* plant extract as a candidate drug for the treatment of glioblastoma.

**Key words:** *Scilla autumnalis*; glioblastoma; cancer treatment

## ÖZET

**Amaç:** Bu çalışmada U87 glioblastoma hücre hattı üzerinde bitkisel temelli kemoterapötik olarak davranma potansiyeli taşıyan *Scilla autumnalis* özütünün etkisinin ölçülmesi amaçlanmıştır.

**Materyal ve Metot:** Sitotoksikite deneyleri örneklerin canlılığının MTT (3 – (4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) yöntemiyle belirlenmesiyle saptanmıştır. Glioblastoma hücrelerindeki Glukoz transporter 1 (GLUT1), Glukoz transporter 3 (GLUT3), Glukoz transporter 4 (GLUT4), Heksokinaz 1 (HK1) and Heksokinaz 2 (HK2), Multidrug resistance1 (MDR1), Cytochrome P450 Family 2 Subfamily E Member 1 (CYP2E1) ve Pregnane X receptor (PXR) gen anlatım düzeyleri kantitatif RT-PCR kullanılarak analiz edilmiştir.

**Bulgular:** Elde edilen sonuçlara göre GLUT1 anlatımı %10 düzeyinde artarken GLUT3 anlatımında bir değişiklik saptanmamıştır. Kök etanol özütü GLUT4 anlatımını %13 kadar azaltırken gövde özütü %5–6 civarında artırmıştır. Glioblastomadaki HF1 ve HK2 anlatım düzeyleri kontrol grubuna göre önemli ölçüde düşük olarak bulunmuştur. *S.autumnalis* kök özütü MDR1 anlatımında küçük bir miktar artışa yol açmıştır. CYP2E1'nin anlatım düzeyinin *S. autumnalis*'in kök ve gövde özütü uygulanmış glioblastoma hücrelerinde kontrol grubuna göre %20 oranında düştüğü saptanmışken PXR anlatımının da azaldığı gözlemlenmiştir.

**Sonuç:** Bu çalışma *S.autumnalis*'in sitotoksik etkisinin anlaşılmasına önemli bir katkı sunabilir. Bu yaklaşım *S.autumnalis* bitki özütünün glioblastoma tedavisinde aday ilaç olarak kullanılabileceğine işaret etmektedir.

**Anahtar kelimeler:** *Scilla autumnalis*; glioblastoma; kanser tedavisi

**İletişim/Contact:** Murat Pekmez, Istanbul University Faculty of Science, Department of Molecular Biology and Genetics, Istanbul, Turkey • Tel: 0536 277 43 17 • E-mail: mpekmez@istanbul.edu.tr • Geliş/Received: 24.09.2020 • Kabul/Accepted: 13.06.2021

**ORCID:** Murat Pekmez, 0000-0002-6150-8372 • Çağatay Tarhan, 0000-0001-5265-4610 • Ali Zeytinluoğlu, 0000-0002-2534-7241 • Murat Turan, 0000-0003-2900-1755 • Şefika Beyza Mete, 0000-0002-3386-6244 • Aylin Koseler, 0000-0003-4832-0436

## Introduction

Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor in adults, which is also difficult to diagnose and treat. The treatment has not changed over the years<sup>1,2</sup>. 90% of cases develop de novo (primary glioblastoma) from normal glial cells with multistep tumorigenesis. The remaining 10% glioma is secondary neoplasm cases that progress from low-grade tumors (diffuse or anaplastic astrocytomas) lasting 4–5 years<sup>3,4</sup>. The main developmental location of glioblastoma multiforme is the brain. The tumor is indistinguishable from normal tissue because it is characterized by infiltrating growth<sup>1,5</sup>. It is localized in the hemispheres or subcutaneously in the brain stem and the cerebellum<sup>6,8</sup>. The result may sometimes be hydrocephaly, as a growing tumor causes increased intracranial pressure<sup>9</sup>.

As it is known, cancer, which caused approximately 8.2 million deaths in 2012, is one of the most common diseases<sup>10</sup>. The effect of various risk factors, including age, geographical region, and race, on cancer development, has been reported<sup>11</sup>. Although chemotherapy is the main treatment approach, resistance to chemotherapeutic drugs has been observed in 30–80% of cancer patients in recent years. Therefore, plant-based substances have received great interest among researchers. Plant kingdom comprised approximately 250 000 plant species but nearly 10% of them have been studied for the treatment of different diseases. That's why it is important to evaluate the potential of untested or endemic plant species extracts or their purified compounds.

The Hyacinthaceae family has approximately 900 species in about 70 genera in the world<sup>12</sup>. *Scilla* species are widely used in folk medicine in the treatment of different illnesses. As phytochemical compounds, the alkaloids, cardiac glycosides, ergosterol glycosides, triterpenoids, triterpenoids glycosides, nortriterpenoids glycosides, stilbenes, and homoisoflavanoids was reported<sup>13,14</sup>. These compounds are responsible for a large number of different biological activities such as analgesic<sup>15,16</sup>, anti-tumoral<sup>12,17–20</sup>, anti-inflammatory<sup>16,21–24</sup>, anti-oxidative<sup>22</sup>, and antioxidant<sup>24–26</sup>.

*Scilla autumnalis* is found in the Mediterranean region from Portugal to Turkey and the Caucasus<sup>26</sup>. There are only a few data on the anti-tumoral activity of the *Scilla* species, however, there are no data on the anti-tumoral activity of *Scilla autumnalis*. In the present study, we assessed the anti-tumoral effects of *Scilla autumnalis* extracts on glioblastoma multiforme.

## Materials and Methods

### Preparation of Plant Extract

*Scilla autumnalis* was collected from Denizli, Turkey. The herbarium sample was separated from the collected plant samples and stored in the Herbarium of the University of Pamukkale, Denizli, Turkey (Voucher specimen number: RM1002). Systematic identification of the collected plant species was made using reference books and identification keys.

The plant extraction was performed with method described by Mammadov et al.<sup>26</sup> Firstly, the root (7) and shoot (8) parts of plants were dried in the shade and were powdered with grinder. 10 g plant sample was added into erlenmeyer which contains 100 mL solvent [ethanol (G) or methanol (H)] and then shaken at 50° C for 6 h. The solvent extract was filtered and evaporated using rotary evaporator. The dry solvent extract was solved with distilled water and was frozed at –80° C. The frozed sample was lyophilized with lyophilizer. Obtained extracts were stored at –20° C until use.

### U87 Glioblastoma Cell Line

U87 MG cells were used from the cell culture collection of Molecular Biology and Genetics Department, Istanbul University. The cells that were used in the experiments had a passage number between 6–9. Glioblastoma cells were grown and subcultured in Dulbecco's Modified Eagle Medium (DMEM) supplemented with Glucose (4.5 mg/mL), 10% Fetal Bovine Serum (FBS), 1% antibiotics and antimycotic (penicillin, streptomycin and amphotericin B) and 1% non-essential amino acids (NEAA) at 37° C with 5% CO<sub>2</sub> in an incubator.

### Cytotoxicity Assay

Cytotoxicity assays were performed by determining the cell viability of the samples with MTT (3 – (4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) assay Briefly, U87MG cells (1.5x10<sup>4</sup> per well) were seeded in 96-well plates and incubated at 37° C for 24 h. Different concentrations of 7G, 8G, 8H (1, 5, 10, 25, 50, 100, 250, 500, 1000 µg/mL) were tested on the cells for 24, 48 and 72 h. After treatments, the cells were incubated with MTT at a final concentration of 0.5 mg/ml at 37° C for 4 h, followed by the addition of DMSO (150 µl) to dissolve the formazan crystals. The absorbance of each well was measured at 570 nm

using a microplate reader (EON, BioTek Instruments Inc., Winooski, VT, USA). Half-maximal inhibitory concentrations ( $IC_{50}$ ) of the extracts were calculated by fitting the data to a sigmoidal dose-response curve using nonlinear regression analysis. All test samples were measured in triplicate.

### Gene Expression Analysis Using Quantitative Real-time RT-PCR Analysis

Gene expression of GLUT1 (SLC2A1), GLUT3 (SLC2A3), GLUT4 (SLC2A4), Hexokinase 1 (HK1) and Hexokinase 2 (HK2), MDR, CYP2E1, PXR was analyzed in glioblastoma cells. After 48 hours of treatment with *S. autumnalis* root (ethanol) and shoot ethanol and methanol extracts, total RNA was extracted with Human Blood RNA Purification Kit (GMBiolabs, Taichung City, Taiwan) according to the procedure recommended by the manufacturer. Conversion of total RNA to single-strand complementary DNA (cDNA) was done with High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems Inc., Foster City, CA, USA) with random primers. Real-time PCR was performed with GM SYBR qPCR Kit (without ROX) (GMBiolab, Taichung City, Taiwan) with the specified conditions as initial denaturation at 95 °C for 120 seconds (sec.), following 45 cycles at 95 °C for 20 sec., at 55 °C for 30 sec., at 72 °C for 45 sec. Primer sequences and expected product lengths are given in Table 1. Expression of each target genes was normalized to the expression of Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH).

**Table 1.** Primers used in quantitative real-time RT-PCR

Gene	Forward Primer 5'→3'	Reverse Primer 5'→3'
HK1	TCAGATCGAGAGTGACCGATT	CACACTGTCTTGACGAGGATAC
HK2	ACGAGAGTTTCCTGGTCTCA	TCAAAGTCCCTCTCCTCTG
GLUT1	GTTTCATCGTGGCTGAACTCT	ACAGTTGCTCCACATACTGG
GLUT3	CGCCTGATTATTGGCATCTT	TCCAAACCAAAGACCTGAGC
GLUT4	CAGTATGTTGCGGAGGCTAT	AGTTCTGTGCTGGGTTTCAC
CYP2E1	ATGTCTGCCTCGGAGTGA	GGAAGAGGTTCCCGATGATG
MDR	TGGACCCAGCACAATGAA	CTAAGTCATAGTCCGCTAGAAGCA
PXR	GGCCACTGGCTATCACTTCAA	GTTTCATGGCCCTCCTGAAA

HK1, hexokinase 1; HK2, hexokinase 2; GLUT1, glucose transporter 1; GLUT3, glucose transporter 3; GLUT4, Glucose transporter 4; MDR1, multidrug resistance 1; CYP2E1, Cytochrome P450 Family 2 Subfamily E Member 1; PXR, Pregnane X receptor.

### Statistical Analysis


Statistical software Graph Pad Prism 6.0 (Graph Pad, San Diego, CA) was used for all statistical analyses.  $IC_{50}$  values were calculated with non-linear regression analysis.

### Results


**Cytotoxicity on glioblastoma cells.** To evaluate the cytotoxic effects of extracts on U87MG cells and determine  $IC_{50}$  value, the MTT cell viability test was performed after 24 h, 48 h, and 72 h. In the experiments, the final DMSO concentration did not exceed 0.75% and this concentration does not affect cell viability. The results showed that all of the extracts (7G, 8G, and 8H) inhibit U87MG cell proliferation in a dose-dependent manner. For further experiments 48 h incubation was chosen and  $IC_{50}$  values were calculated as 79.04  $\mu\text{g}/\text{mL}$ , 237.342  $\mu\text{g}/\text{mL}$ , 188.919  $\mu\text{g}/\text{mL}$  respectively for 7G, 8G, and 8H. The ethanolic root extract has the most inhibitory effect on the U87 glioma cell line. The effect of different extracts on the survival of the U87 glioblastoma cell line was shown in Fig 1, Fig 2, and Fig 3. In our study, gene expression of GLUT1 (SLC2A1), GLUT3 (SLC2A3), GLUT4 (SLC2A4), Hexokinase 1 (HK1) and Hexokinase 2 (HK2), MDR, CYP2E1, PXR was analyzed. The expression profile of the groups was shown in Fig 4.

### Discussion


85–90% of primary central nervous system (CNS) tumors are brain tumors. Glioblastoma (GBM) accounts for approximately half of all malignant adult brain tumors and is associated with the shortest survival<sup>27</sup>. After the resistance to chemotherapeutics, natural product-based therapy has started to be used. This method has gained popularity as a potentially less toxic treatment. Podophyllotoxin and its semi-synthetic derivatives, Teniposide, Etoposide, and Etopophos, have been extensively used to treat many cancers<sup>28</sup>. Plant-based products have long been involved in cancer treatment. Their effect in this treatment is used to influence cancer development, progression, and metastasis. Some studies have demonstrated antitumor potential in the use of this plant-based therapy alone or combination with radiotherapy. During the 1960 s and 1985 s, the National Cancer Institute (NCI) conducted an anti-cancer drug screening program. In this screening,




**Figure 1.** Effect of *Scilla autumnnalis* root ethanolic (7G), shoot ethanolic (8G) and shoot methanolic (8H) extracts on the survival of U87 glioblastoma cells. Serially diluted (1-1000 µg/mL) extracts were added on U87 cells and incubated for 24 hours. Cell viability was evaluated with MTT assay. Line graphs were obtained with GraphPad Prism 7.0.



**Figure 2.** Effect of *Scilla autumnnalis* root ethanolic (7G), shoot ethanolic (8G) and shoot methanolic (8H) extracts on the survival of U87 glioblastoma cells. Serially diluted (1-1000 µg/mL) extracts were added on U87 cells and incubated for 48 hours. Cell viability was evaluated with MTT assay. Line graphs were obtained with GraphPad Prism 7.0.



**Figure 3.** Effect of *Scilla autumnnalis* root ethanolic (7G), shoot ethanolic (8G) and shoot methanolic (8H) extracts on the survival of U87 glioblastoma cells. Serially diluted (1-1000 µg/mL) extracts were added on U87 cells and incubated for 72 hours. Cell viability was evaluated with MTT assay. Line graphs were obtained with GraphPad Prism 7.0.



**Figure 4.** Gene expression of Hexokinase 1 (HK1) and Hexokinase 2 (HK2), Glucose transporter 1 (GLUT1), Glucose transporter 3 (GLUT3), Glucose transporter 4 (GLUT4), multidrug resistance 1 (MDR1), Cytochrome P450 Family 2 Subfamily E Member 1 (CYP2E1) and Pregnane X receptor (PXR). *Scilla autumnnalis* root ethanolic (7G), shoot ethanolic (8G) and shoot methanolic (8H) extracts.

an important compound, Taxol (paclitaxel) isolated from the bark of *Taxus brevifolia*, used to treat many solid tumors, was identified<sup>29,30</sup>.

It has been investigated the toxicological properties of *Scilla* species in the various cancer cell lines: A 15-deoxoeucosterol oligosaccharide isolated from *Scilla peruviana* L. was found to be toxic to against cervical cancer (HeLa cells)<sup>12</sup>. The four compounds isolated from *Scilla luciliae* was showed the cytotoxic activity against Human Oral Squamous Cell Carcinoma (HSC-2) cells<sup>31</sup>. The homoisoflavanones isolated from *Scilla nervosa* have been effective significantly against colon cancer (HT-29) and breast cancer (MDAMB-435) cell lines<sup>20</sup>. Scillascillin isolated from the fresh bulb of *Scilla scilloides* showed significantly active against human cancer cell lines MCF-7 (breast cancer) and DU-145 (prostate cancer)<sup>32,33</sup>. The scilla scilloside E-1 isolated from *Scilla scilloides* were evaluated for their cytotoxic

activity against eight cancer lines in vitro and in vivo experiments. Particularly, it was found to be more effective against Fibrosarcoma Tumor (HT1080)<sup>19</sup>. The phenolic compounds isolated from *Scilla autumnnalis* was showed a significant effect against human lung cancer (H1299) in vitro conditions<sup>26</sup>. Research studies have shown that *Scilla* species are associated with many types of cancer and have demonstrated their effectiveness.

When we investigated the inhibitory effect of *S. autumnnalis* extracts on the proliferation of U87 cells, we observed that 500 µg/ml of both root and shoot extracts decreased the survival of more than 50% in all tested conditions. However, root extract was more effectively such that even 100 µg/ml inhibited U87 cells by 50%. This indicates the importance of analyzing especially the root content and revealing effective compounds.

Enhanced glycolysis is one of the most important cancer metabolic hallmarks<sup>34,35</sup>. In neurons, glucose uptake is facilitated by a family of glucose transporters (GLUTs) with the glucose transporter 1 (GLUT1) and 3 isoforms are believed to be responsible for the majority of glucose uptake within the brain<sup>36</sup>. As early as 1992, differential expression of glucose transporters has been noted in various grades of glioma, with an observed upregulation of GLUT1, the most prevalent type of GLUT<sup>37</sup>. There was contention as to whether GLUT1 was overexpressed<sup>37</sup> or underexpressed<sup>38</sup> in GBM, but it is now believed that there are areas of which both increase and decrease in GLUT1 expression was observed in GBM tissue<sup>39</sup>. The most significant overexpression of the glucose transporters was observed in the intermediate zone of the tumor<sup>40</sup>. In this study, we observed a 10% increase in the expression of Glut1 following the treatment of *Scilla autumnalis*, however, we did not observe the differences in glucose transporter 3 (GLUT3) expression. In another study, it was observed in biopsied glioblastoma that while expression of GLUT1 and GLUT3 was not significantly changed, glucose transporter 4 (GLUT4) expression was relatively low<sup>41</sup>. In our study, following *Scilla autumnalis* extract treatment for 48 hours, we observed a 10% increase in the expression of Glut1, however, we did not observe a difference in Glut 3 expression. As for Glut4, root ethanol extract decreased its expression by 13% but shoot extracts elevated the expression levels by only 5–6%. In various studies, different extracts or even purified phytochemicals showed variable effects on GLUT gene expression depending on the cancer type. For example, Resveratrol, a trihydroxystilbene, inhibited GLUT1 and thereby the glucose uptake in human leukemic cell lines<sup>42</sup>. Similarly, Rubusoside (a steviol glycoside), curcumin (flavanoid) and plumbagin (naphthoquinone) have also been shown to have a down-regulating activity on GLUT1 expression<sup>43,44</sup>. On the other hand, daidzein (isoflavone) and epigallocatechin gallate (catechin) cause elevated GLUT1 expression in breast cancer. Thus, differential expression of GLUT genes may result from combined effects of the phytochemical content of the root.

The Cytochrome P450 enzyme family contains several subcategories (CYP1, CYP2, and CYP3) which are responsible for the breakdown of foreign compounds in mammals. Cytochrome P450 Family 2 Subfamily E Member 1 (CYP2E1) can also activate toxic compounds and procarcinogens found in tobacco smoke and nitrosamine compounds<sup>45</sup>. In the

previous study; it has been determined as slightly induced with *Scilla nervosa* aqueous extract of CYP3A4 activity<sup>46</sup>. In our study, we found that the expression level of CYP2E1 was 20% lower in glioblastoma cells treated with *Scilla autumnalis* root and shoots extracts compared to the control group. Because CYP2E1 metabolizes the aforementioned molecules and pro-carcinogens such as nitrosamines and azo compounds<sup>47</sup> and metabolism of these molecules produce toxic intermediates and reactive oxygen species that cause various pathological conditions<sup>48</sup>, elevated expression of CYP2E1 may also be responsible for cancer progression. A study, suggest a possible link between CYP2E1 activity and breast cancer through ethanol metabolism<sup>49</sup>. On the other hand, it was shown in another study that CYP2E1 is upregulated in the nontumor tissue and downregulated in tumor tissue in hepatocellular carcinoma<sup>50</sup>. Thus, a natural therapeutic target must be evaluated in each cancer cell type.

P-glycoprotein (P-gp), a 170-kDa protein encoded by the multiple drug resistance human (MDR1) gene, which is a member of the ABC superfamily of energy-dependent transport systems. P-gp displays broad specificity, accepting many structurally, functionally, and mechanistically unrelated compounds and its role in limiting drug penetration across biological barriers is well established<sup>51</sup>. An enhancement of ABC transporter expression represents one of the major MDR mechanisms that protect cancer cells from different drugs. Nardinocchi et al. observed that the downregulation of HIF-1 $\alpha$  was associated with a decrease in MDR1 transcript levels<sup>51</sup>. In this study, we observed that especially *S. autumnalis* root extract led to a slight increase in MDR1 expression. Although it can be considered as a drawback for the outcome of chemotherapy, the root extract itself is more toxic to glioblastoma cells than shoot extracts even lower doses. So it seems that the total effect of the extract on glioblastoma overshadows this slight increase.

Pregnane X receptor (PXR) are known major nuclear transcription factors in regulating drug efflux transporters and also plays a role in cell proliferation, apoptosis, carcinogenesis and cancer treatments<sup>52</sup>. PXR can alter the outcome of chemotherapy in different cancers by regulating especially drug metabolism, drug transport, proliferation, and apoptosis. But it seems that the PXR expression may be context-specific in these cancers. For example, it was reported that, in human prostate cancer,

PXR expression was higher in cancerous tissues when compared to normal tissues<sup>53</sup>. In breast cancers, some studies suggested elevated PXR expression in cancer tissue<sup>54</sup> but others reported no significant difference in the expression between healthy and cancerous tissues<sup>55</sup>. Besides, in breast cancer, pharmacologic induction of PXR causes a significant expression of MDR1 and resistance to Taxol<sup>56</sup>. According to our results, *S. autumnalis* extract downregulated the PXR expression. This reflects the importance of cancer type or the context specificity when an anti-cancer plant, natural product or a drug is considered as a therapeutic agent.

Hexokinases (HK) are comprised of a family of four isoforms. Hexokinase 1 (HK1) and Hexokinase 2 (HK2) are the most abundant, with HK1 (“the brain HK”) ubiquitous in most tissues, especially brain and red blood cells where glycolysis plays a critical role in energy production. When compared to normal cells, tumor cells preferentially utilize this far less efficient process for ATP production, which also increased the cell’s proliferation, invasiveness, and apoptosis resistance. This high rate of glycolysis in tumor cells, including glioma cells, was presumably ascribed to the up-regulation of key catalytic enzymes in glycolysis, especially hexokinases, more specifically HK2. In addition to its critical metabolic role, HK2 could also promote glioma survival, against chemo or radiation insult, by repressing mitochondria-mediated apoptotic pathway in glioma cells<sup>57</sup>. Here in this study, we determined the low expression levels of HK1 and HK2 in glioblastoma compared to the control group. In two different studies, the inhibition of HK2 by some chemicals such as 2-deoxy-D-glucose (2-DG) or by 3-bromopyruvate (3BP) was shown to inhibit glycolysis in tumor cells<sup>58,59</sup>. But the potential toxicity of these chemicals to normal cells limits their use in cancer treatment. Therefore, it becomes very important to find natural products that do not have such side effects. In this study, we determined the expression levels of HK1 and HK2 in glioblastoma were nearly 55% lower than the control group when treated with *S. autumnalis* root and shoot extracts. Several phytochemicals exert HK2 downregulating activity. For example, a bioactive flavone chrysin was shown to decrease of HK2 expression, thereby glucose uptake and tumor glycolysis in hepatocellular carcinoma (Chrysin inhibited tumor glycolysis and induced apoptosis in hepatocellular carcinoma by targeting HK2). Other compounds, such as betulinic acid and ursolic acid also have HK2 downregulating activity<sup>60</sup>.

All these results suggest that despite the other effects of *S. autumnalis* plant extract, the cytotoxic effect on glioblastoma is mediated by reducing the level of HK1 and HK2 expressions. *S. autumnalis* plant extract may be a candidate, especially for glioblastoma treatment drugs. Mechanism of action, chemical properties for the usage in glioblastoma and the effect of the extract on glioblastoma could be the further issues to be considered.

#### Authors’ Contributions

A. K., Ç. T., M. P., and A. Z. designed the study. A. K., Ç. T., M. P., and A. Z. analyzed data. A. K., M. T., and Ş. B. M. performed experiments, A. K., Ç. T., M. P., and A. Z. contributed ideas and insights. A. K., Ç. T., M. P., and A. Z. wrote the article with input from all Authors.

#### Conflicts of Interest

The authors declare no competing interests regarding this study.

#### References

1. Karcher S, Steiner HH, Ahmadi R, Zoubaa S, Vasvari G, Bauer H et al. Different angiogenic phenotypes in primary and secondary glioblastomas. *Int J Cancer* 2006;18:2182–2189.
2. Moore MP, Bagley RS, Harrington ML and Gavin PR. Intracranial tumours. *Clin North Am Small Anim Pract Vet* 1996;26:759–777.
3. Kabat GC, Etgen AM and Rohan TE. Do steroid hormones play a role in the etiology of glioma? *Cancer Epidemiol Biomarkers Prev* 2010;19:2421–27.
4. Tso CL, Freije WA, Day A, Chen Z, Merriman B, Perlina A, et al. Distinct transcription profiles of primary and secondary glioblastoma subgroups. *Cancer Res* 2006;66:159–167.
5. Zhen L, Yufeng C, Zhenyu S and Lei X. Multiple extracranial metastases from secondary glioblastoma multiforme: a case report and review of the literature. *J Neurooncol* 2010;99:165–176.
6. Krex D, Klink B, Hartmann C, von Deimling A, Pietsch T, Simon M, et al. Long-term survival with glioblastoma multiforme. *Brain* 2007;130:2596–2606.
7. Lakhani SE and Harle L. Difficult diagnosis of brainstem glioblastoma multiforme in a woman: a case report and review of the literature. *J Med Case Rep* 2009;3:87.
8. Hur H, Jung S, Jung TY and Kim IY. Cerebellar glioblastoma multiforme in an adult. *J Korean Neurosurg Soc* 2008;43(4):194–197.
9. De Castro-Costa CM, de Araújo RW, de Arruda MA, de Araújo PM and de Figueiredo EG. Increased intracranial pressure in a case of spinal cervical glioblastoma multiforme. Analysis of these two rare conditions. *Arq Neuropsiquiatr* 1994;52:64–8.

10. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A(2015)Global cancer statistics, 2012. *CA Cancer J Clin* 65(2):87–108.
11. Millimouno FM, Dong J, Yang L, Li J, and Li X. Targeting apoptosis pathways in cancer and perspectives with natural compounds from mother nature. *Cancer Prev Res (Phila)*2014;7(11):1081–1107.
12. Mulholland DA, Schwikkard SL and Crouch NR. The chemistry and biological activity of the Hyacinthaceae. *Nat Prod Rep* 2013;30(9):1165–1210.
13. Ghoran SF, Pouneh Ebrahimi P, Hossein Mighani H and Soudabeh Saeidnia S. Isolation and characterization of homoisoflavonoids from *Scilla persica* Hausskn. *Brazilian Journal of Pharmaceutical Sciences* 2015;51(4):949–955.
14. Ghoran SF, Saeidnia S, Babaei E, Kiuchi F and Hussain H *Scilla persicene*: a new homoisoflavonoid with cytotoxic activity from the bulbs of *Scilla persica* Hausskn. *Natural Product Research* 2016;30(11):1309–1314.
15. Kalaiselvan M and Gopalan R. Ethnobotanical studies on selected wild medicinal plants used by Irula tribes of bolampatty valley, nilgiri biosphere reserve (NBR), southern Western Ghats, India. *Asian Journal of Pharmaceutical and Clinical Research* 2014;7(1):22–26.
16. Du Toit K, Kweyama A and Bodenstein J. Anti-inflammatory and antimicrobial profiles of *Scilla nervosa* (Burch.) Jessop (Hyacinthaceae). *South Afr J Sci* 2011;107(5–6):96–100.
17. Clark AM. Natural Products as a Resource for New Drugs. *Pharmaceutical Research* 1996;13(8):1133–1141.
18. Mimaki Y, Nishino H, Kuroda M, Matsui T and Sashida Y. Lanosterol Oligosaccharides from the Plants of the Subfamily Scilloideae and Their Antitumor Promoter Activity. *Chemical and Pharmaceutical Bulletin* 1994;42(2):327–332.
19. Lee HB and Lee SM. Antimicrobial Activity of Eucosterol Oligosaccharides Isolated from Bulb of Squill (*Scilla scilloides*). *Pharmacology & Pharmacy* 2013;4:110–114.
20. Abegaz BM. Novel phenylanthraquinones, isofuranonaphthoquinones, homoisoflavonoids, and biflavonoids from African plants in the genera *Bulbine*, *Scilla*, *Ledebouria*, and *Rhus*. *Phytochem Rev* 2002;1:299–310.
21. Sakthivel K, Palani S, Selvaraj R, Venkadesan D, Sivasankari H and Senthil Kumar B. Cardioprotective and Antioxidant Potential of *Scilla hyacinthina*. *Journal of Biological Sciences* 2013;13(5):313–322.
22. Yeo EJ, Kim KT, Han YS, Nah YS and Paik HD. Antimicrobial, anti-inflammatory and anti-oxidative activities of *Scilla scilloides* (Lindl.) Druce root extract. *Food Sci Biotechnol*, 2006;15:639–642.
23. Nishida Y, Sugahar S, Kensuke Wada K, Toyohisa D, Tanaka T, Ono M et al. Inhibitory effects of the ethyl acetate extract from bulbs of *Scilla scilloides* on lipoxygenase and hyaluronidase activities. *Pharmaceutic al Biology* 2014;52(10):1351–1357.
24. Alluri N, Ravi BV, Kumari H, Latha P, MAjumdar M. Evaluation of in vitro antioxidant, anti-inflammatory and thrombolytic activities of *Scilla hyacinthina*, an endangered medicinal plant. *International Journal of Pharmacy and Pharmaceutical Sciences* 2015;7(4):84–88.
25. Gupta LM and Raina R. Antioxidant property of the bulb of *Scilla indica*. *Current Science* 2001;80(10):1267–1269.
26. Mammadov R, Kaska A, Ozay C. Phenolic Composition, Antioxidant and Cytotoxic Activities of *Prospero autumnale*. *Indian Journal of Pharmaceutical Sciences* 2017;79(4):585–590.
27. Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008–2012. *Neuro Oncol* 2015;17: iv1-iv62.
28. Schacter L. Etoposide phosphate: what, why, where, and how? *Semin Oncol* 1996;23:1–7.
29. Mann J. Natural products in cancer chemotherapy: past, present and future. *Nat Rev Cancer* 2002;2:143–148.
30. Altmann KH and Gertsch J. Anticancer drugs from nature-natural products as a unique source of new microtubule stabilizing agents. *Nat Prod Rep* 2007;24:327–357.
31. Ori K, Kuroda M, Mimaki Y, Sakagami H and Sashida Y. Lanosterol and Tetranorlanosterol glycosidised from the bulbs of *Muscari paradoxum*. *Phytochemistry* 2003;64(8):1351–1359.
32. Wang YM, Fan MY, Li J, Wang ZM, Gao HM. Homoisoflavonones and stilbenes from fresh bulb of *Scilla scilloides*. *Zhongguo Zhong Yao Za Zhi* 2014;39(19):3788–3793.
33. Chinthala Y, Chinde S, Kumar AN, Srinivas KV, Kumar JK, Sastry KP, et al. Anticancer Active Homoisoflavone from the Underground Bulbs of *Ledebouria hyderabadensis*. *Pharmacognosy Res* 2014;6(4):303–5.
34. Cantor JR and Sabatini DM. Cancer cell metabolism: one hallmark, many faces. *Cancer Discov* 2012;2(10):881–898.
35. Hanahan D and Weinberg RA. Hallmarks of Cancer: The Next Generation. *Cell* 2011;144:646–674.
36. Duelli R and Kuschinsky W. Brain glucose transporters: relationship to local energy demand. *News Physiol Sci* 2001;16:71–76.
37. Nishioka T, Oda Y, Seino Y, Yamamoto T, Inagaki N, Yano H et al. Distribution of the glucose transporters in human brain tumors. *Cancer Res* 1992;52:3972–3979.
38. Tsukamoto H, Boado RJ and Pardridge WM. Differential expression in glioblastoma multiforme and cerebral hemangioblastoma of cytoplasmic proteins that bind two different domains within the 3'-untranslated region of the human glucose transporter 1 (GLUT1) messenger RNA. *J Clin Invest* 1996;97:2823–2832.
39. Pistollato F, Abbadi S, Rampazzo E, Persano L, Della Puppa A, Frasson C. Intratumoral hypoxic gradient drives stem cells distribution and MGMT expression in glioblastoma. *Stem Cells* 2010;28:851–862.
40. Pistollato F, Rampazzo E, Persano L, Abbadi S, Frasson C, Denaro L et al. Interaction of hypoxia-inducible factor-1alpha and Notch signaling regulates medulloblastoma precursor proliferation and fate. *Stem Cells* 2010;28:1918–1929.
41. Nagamatsu S, Sawa H, Wakizaka A and Hoshino T. Expression of facilitative glucose transporter isoforms in human brain tumors. *J Neurochem* 1993;61(6):2048–2053.

42. Zambrano A, Molt M, Uribe E and Salas M. Glut 1 in Cancer Cells and the Inhibitory Action of Resveratrol as A Potential Therapeutic Strategy. *Int J Mol Sci* 2019;20(13):3374.
43. George Thompson AM, Iancu CV, Nguyen TT, Kim D and Choe JY. Inhibition of human GLUT1 and GLUT5 by plant carbohydrate products; insights into transport specificity. *Sci Rep* 2015;26(5):12804.
44. Liao H, Wang Z, Deng Z, Ren H and Li X. Curcumin inhibits lung cancer invasion and metastasis by attenuating glut1/mt1-mmp/mmp2 pathway. *Int J Clin Ex. Med* 2015;8:8948–8957.
45. García-Suástegui WA, Ramos-Chávez LA, Rubio-Osornio M, Calvillo-Velasco M, Atzin-Méndez JA, Guevara J et al. The Role of CYP2E1 in the Drug Metabolism or Bioactivation in the Brain. *Oxid Med Cell Longev* 2017;4680732.
46. Pillay P, Phulukdaree A, Chaturgoon AA, Du Toit K and Bodenstern J. The cytotoxic effects of *Scilla nervosa* (Burch.) Jessop (Hyacinthaceae) aqueous extract on cultured HepG2 cells. *J Ethnopharmacol* 145(1)2013;(1):200–204.
47. Gonzalez FJ. Mutant Role of cytochromes P450 in chemical toxicity and oxidative stress: studies with CYP2E1. *Res* 2005;569(1–2):101–110.
48. Knockaert L, Fromenty Band Robin MA. Mechanisms of mitochondrial targeting of cytochrome P450 2E1: physiopathological role in liver injury and obesity. *FEBS J* 2011;278(22):4252–4260.
49. Leung T, Rajendran R, Singh S, Garva R, Krstic-Demonacos M and Demonacos C. Cytochrome P450 2E1(CYP2E1) regulates the response to oxidative stress and migration of breast cancer cells. *Breast Cancer Res* 2013;15(6): R107.
50. Ho JC, Cheung ST, Leung KL, Ng IO and Fan ST. Decreased expression of cytochrome P450 2E1 is associated with poor prognosis of hepatocellular carcinoma. *Int J Cancer* 2004;111(4):494–500.
51. Da Ros M, De Gregorio V, Iorio AL, Giunti L, Guidi M, de Martino M, et al. Glioblastoma Chemoresistance: The Double Play by Microenvironment and Blood-Brain Barrier. *Int J Mol Sci* 2018;19(10): pii: E2879.
52. Zhuo W, Hu L, Lv J, Wang H, Zhou H and Fan L. Role of pregnane X receptor in chemotherapeutic treatment. *Cancer Chemother Pharmacol* 2014;74(2):217–227.
53. Chen Y, Tang Y, Wang MT, Zeng S, Nie D. Human pregnane X receptor and resistance to chemotherapy in prostate cancer. *Cancer Res* 2007;67:10361–10367.
54. Conde I, Lobo MV, Zamora J, Perez J, Gonzalez FJ, Alba E, et al. Human pregnane X receptor is expressed in breast carcinomas, potential heterodimers formation between hPXR and RXR-alpha. *BMC Cancer* 2008;8:174.
55. Qiao EQ and Yang HJ. Effect of pregnane X receptor expression on drug resistance in breast cancer. *Oncology letters* 2014;7:1191–1196.
56. Chen Y, Tang Y, Chen S and Nie D. Regulation of drug resistance by human pregnane X receptor in breast cancer. *Cancer Biol Ther* 2009;8:1265–1272.
57. Liu H, Liu N, Cheng Y, Jin W, Zhang P, Wang X. Hexokinase 2(HK2), the tumor promoter in glioma, is downregulated by miR-218/Bmi1 pathway. *PLoS One* 2017;12(12): e0189353.
58. Zhang D, Li J, Wang F, Hu J, Wang S and Sun Y 2-Deoxy-D-glucose targeting of glucose metabolism in cancer cells as a potential therapy. *Cancer Lett* 2014;355(2):176–83.
59. Azevedo-Silva J, Queiros O, Baltazar F, Ulaszewski S, Goffeau A, Ko YH et al. The anticancer agent 3-bromopyruvate: a simple but powerful molecule taken from the lab to the bedside. *J Bioenerg Biomembr* 2016;48(4):349–362.
60. Lewinska A, Adamczyk-Grochala J, Kwasniewicz E, Deregowska A and Wnuk M. Ursolic acid-mediated changes in glycolytic pathway promote cytotoxic autophagy and apoptosis in phenotypically different breast cancer cells. *Apoptosis* 2017;22(6):800–815.